Trial intelligence / Profile preview

ADME study of radiolabeled INC280 in healthy male volunteers

NL-OMON41012Active, not recruiting

Sponsor
Novartis
Start
Nov 2014
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Open-label, single-arm trial of capmatinib in cancer, sponsored by Novartis. Started Nov 2014; status: active, not recruiting.

02

Drugs

capmatinib
03

Conditions

cancer

Beyond the preview

Go deeper on NL-OMON41012.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON41012.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call